Skip to content
Menu

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.

Read at benzinga.com